Two thirds of world’s population join COVAX Facility for equitable access to COVID-19 vaccines: WHO

Geneva, Switzerland | XINHUA | A total of 156 economies representing nearly two-thirds of the world’s population have joined the COVAX Facility, an international initiative co-led by the World Health Organization (WHO) and partners to ensure equitable global access to COVID-19 vaccines, the WHO said on Monday.

This includes 64 higher-income economies, which are self-financing in procuring COVID-19 vaccines once available, and 92 low- and middle-income economies eligible for support for the procurement of vaccines through the COVAX Advance Market Commitment (AMC) coordinated by the Gavi, the Vaccine Alliance, a financing instrument aimed at supporting the procurement of vaccines for these countries.

“This means that 156 economies, representing roughly 64 percent of the global population in total, are now either committed to or eligible for the COVAX Facility, with more to follow,” the WHO said in a statement.

The COVAX Facility is part of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the WHO, in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, civil society organizations and others.

The allocation of COVID-19 vaccines aims at ensuring that no participating economy will be left behind, as policies determining the prioritization of vaccine rollout within economies will be guided by recommendations from the WHO Strategic Advisory Group of Experts on Immunization.

The WHO said that those fully self-financing economies will now unlock vital funding and the security of demand needed to scale up manufacturing and secure the doses needed for the COVAX Facility.

Currently, CEPI is leading COVAX vaccine research and development work, which aims to develop at least three safe and effective vaccines. Nine candidate vaccines are being supported by CEPI, eight of which are in clinical trials. COVAX’s core aim is to have 2 billion vaccine doses available by the end of 2021.

According to the WHO, governments, vaccine manufacturers, organizations and individuals have committed 1.4 billion U.S. dollars towards vaccine R&D so far, but the initial target in seed funding needed by the end of 2020 amounts to 2 billion dollars.

The commitment agreements secured also commit higher income governments to provide an upfront payment to reserve doses by Oct. 9, 2020. These funds will be used to accelerate the scale-up of vaccine manufacturing to secure 2 billion doses of vaccine, enough to vaccinate 1 billion people assuming the vaccine requires a two-dose regimen.

The WHO said that the COVAX Facility will now start signing formal agreements with vaccine manufacturers and developers to secure the doses needed to end the acute phase of the pandemic by the end of 2021.

As the world is in the midst of the COVID-19 pandemic, countries across the globe — including Germany, Britain, China, Russia, France and the U.S. — are racing to find a vaccine.

******

XINHUA